I..!
`
`FUKUOKA JAPAN
`
`ISSN 0386-9784
`
`Vol. 52/1990
`
`52 @ (:s~zh~2~l~6 ’q) ~ 3 "~"
`[m t~)
`Necrotizing Fasciitis ...................................................................................................
`~ ~ff- ¯ ~"" 447
`
`Necrotiaing Faseiitis .................................................. . ....................... i ........................ i~I~ ~-~ ¯ ~--- 449
`Neerotizing Fasciitis ~.5~B I ~] ........................................................................ ~J13~ i~-~ ¯ ~--. ,157
`~_~3g~,;~i~b?¢Z,-ffo b 9 3--~7,© 2~J ............................................................
`~ ~q~’. fl~,--- 462
`~’~:~fl;f~ft~ff2U~’c Mycobacterium marinum )~Ji~/~,~O/J~j ................................. )~2g
`-~.~" ~"" 467
`I0 ~;qJ~l~.4e U J’z~’~,~gs,.~ ....................................................................................... ga~Ji~tl-T- - ~--- 473
`Merkel Cell Tumor ................................................................................................... ~ ~ ’ ~l~’.. 478
`~li~i~:~]~$ok~’.~’~i’#J~’[:;~’fll~:~G~tz Seborrheic Keratosis .................................... ...... :~ El ~ ~... 484
`/]~/Zj{V,~Ja~G.~LIL- Bowen ~ .............................................................................. ~ti~ ~;~ ¯ ~t~-" 488
`a:y )) >,~L ,~ bt~]]~li~/,~ .................................................................................
`~
`:~ ¯ iS... 491
`~td~ J: L~d~~btc~’4:~J~ ............................................................ ~El ~"~- 11!1,,, 495
`’) ~ ~ q-~l~*Z ~ t~ ’) ~ -~ g-~t~-.~ ¯ ~a U -~/)g~ ~-~ t:~’±~ ........................ ~I~’~ ~ ~ ¯ {~.., 500
`Buerger ~ ............................................. ; ................................................................. ~ ,~. ~II~... 503
`~,~JJ~t~7}¢.J: 9~’~-J-7-a’b~’~l~r.~ .............................................................................. ~])l ~J./a~. ’[1t~... 509
`~f~t ~," ¯ I2,’tc~..~t0)- >" ~’~tq~ii~A ........................................................................... glF -~. ~... 514
`[~ ~
`--g~?l~q->’~ .,~ (5) ....................................................................................... ~ ~ - ~... 518
`¢~&~a)~l~r/J~’~’~R~ .......................................................................................... ,~ m ~ ~... 533
`DNA ~/~J~ tz ~J 3: l’g~,e~’~ ....................................................................................... ~#
`¢~.1~Jo*,~a~t~,5~±):l.~-~-,5--~-~ ..................... : ............................. ~
`
`~* ~’~... 540
`~E. ~... 545
`
`~lJ;(~!Lt~-i’DE~a)g/~g}3~ 9 (3) .................................................................................... ~g , ~ u)j.,. 550
`[~ ~
`/~.~TTif,~3)~ 5 ~II,~®~,~a)~F;l ................................................................... ~-T¢ ~-~- ~... 555
`gl~,~a)~J~ ................................................................................................. i~iI~l ~- ~.-. 560
`~;~l~-]Ltlz#t’J-,5 Ketotifen-MR a)~¢.’;~f~j~$f ............................................................... ~El g~" fl!l": 565
`~l~" {~(g{l~.~l~,~,~R.~ E~j"J- ,5 -.9 ~ 7 t~ 4: @ "~ >’ ~)~;;~j~ .............................................
`~;~¢~’~--fl~ ¯ ~-.- 572
`Nifedipine ( 7Y’~ -- I- J: ~4z ~>) ~]f] ©~f~l¢.~-Y ,5 ~’.~j~. ..........................................
`~-~fi~;~ * {~... 577
`
`~{~’~-IHi~I] KP-363 (~ Butenafine) )’ 9 --A~]~ 3: D’~?ilJa)~;~_}~,r-j- ,5:
`~--#tt~®~ ...................................................................................
`
`H~~92~~ ........................................................................
`~t~?0~~ ........................................................................
`H~~53,54~~ ..................................................................
`H~~268,269~~ ...............................................................
`
`/~.::51::2:::’~:~’~’* ".::: :.....
`¯ ¯ ,
`
`~t
`t
`
`"..,’, i
`
`~ ~ ¯ ............................................. 596
`~ ~ ~ ............................................. 623
`
`~~[~ .........
`~ ............ :
`~
`
`ish;nihon J DermatolJ
`
`~je~t US ~l~trig~t Law~
`
`.............. , 7 :’:
`
`;t i’
`
`2
`
`Page 1 of 15
`
`

`

`
`
`VEREESLUREHEseNpuouaiyimsopipupg2wyouayosmuyzo1ogsS
`
`
`
`
`
`OLSRSCOLA-—CAOYRE21Seieee
`
`SOMEO°easSHSIS©SRSYBIS“CEFREGFlTfaa
`
`IiP7Ort4—ChiOkeY1EeRese
`
`
`
`(BeyeHide(SE)WEAANMSYs}
`
`YaHas+Baisy-eee
`
`at ae oe
`Fd
`3td
`
`
`
`
`
`0661‘99F~Z9F“(€)ZS‘aY2YHBA
`
`
`
`vereOME+aed}Hbd+..8Hay+.ES}-Ley
`
`($I:3)AVAMMA,
`
`(ABISaOG:SPS)EENATAGREE
`
`(EDKY(2S)BMGTMees
`
`(2aarit:329)MMM
`
`
`
`
`
`WLeSuG¥BsyposeySurzyoinayN
`
`
`
`
`
`
`
`066%“I9k~2Gr‘(€)Zo‘EN2THRE
`
`D6DSSSBAYA-OKYOMYOFFERCOUYEROV
`ONGESSHMGHANEUBEYDLRYSOLB1M2igsCuNCeE
`
`AGEHS‘WeOUSIRAIG1CUSYS?MMTaEy7RESEO9fASEMMROAKMMRS
`‘BecoLER‘Mp
`
`XPUGUGELISPLAS>CCMACPOR‘AU“Ie
`
`“SDRAMORBSIGRAOA-CONOYYRLu2Bee
`
`ODSSCROBEMBOKCLUYRIMTATSRGERBe>YRSSASOREOCeBEORBENAY*>YseHI@
`
`
`
`"dit“TERNS“Te-EY‘ASITER-GOEMNAMMHO
`
`
`
`
`
`LRASMSOD21zRAL[olsesuaenwsno2000/14dnjIS2%4apiuowumaudsnoo
`
`o
`
`~ ~ ~ ~ ~ ~- ~-I~ ~.~
`
`ORLVEGDHE8ORG‘EY‘TE
`
`
`
`
`
`O66T“Z2T~ELF‘(€)7o‘BAYBA
`
`&
`
`F
`
`Dea°°VMNSDORAOT212h69eeCLSOL
`(BERG|EUR)teeTae
`
`(EPich2SENS)IANALETae
`ZLBIMagUy.TROUNECHSBRENE“BETAeToTgina
`
`‘(SUH&6Ba)WEY€OIG‘>SBMOSHSCMBBT
`
`PMRLCHRMN]SCMONEDKIULABIBeyEB29
`
`
`EAS“CHEMAMCLERABI‘4SseHROWUgxgl
`
`REXCUXTOWASWE‘UBMALMASAMAT‘HS
`
`
`
`CEREUS£2ESAWhOBBWHAWSCabal
`
`m ..~
`
`weRRaxe.aeRRuy.hha*YS.eSrh
`
`
`
`PEERS-SE)ESARWARASEYMS.
`
`HQSehS41PULSESOM
`
`ea Ha ae
`Ld
`
`
`
`WMVOTREBMAwnuowwnisapongoohyy=WsSE
`
`GOaisVine:FE)SesheaeeeAayma
`
`BI+MGA-BH
`
`
`
`
`
`O66T“CLP~29F‘(E)2S‘HATABA
`
`
`
`
`
`FESD2ODBDSUNNGMMBUDETAKeedOEEONIE
`
`PCARADORE
`
`onouepwue*@72ESEOPERHIAOSACARHEYWeSCALIMASSORES2BBVOHBEMT—A‘Ahi@wDS-0
`
`
`
`ada}
`AVEUDSGTIMERARICTIMEEEBSDLosRY‘+o3ritag
`
`Be“AYES©OUNSOUIA‘NNOYOLLaBMCY?Ie823s@(SUE)WNL
`
`
`SIBARGTIOEAORIRSSITI1&©OWA1LVMOCISBNE<(ERINTeSTEER
`"NESBWMSLMLAKTACK°XUNETABHELO
`
`
`
`
`
`
`wnuajsngodsyy{7BRREYCol$4ORIG2uwUSMSSREYBOMMEBE‘GY2Mgt12BARA@wmnuunU
`
`
`OFXOSSLEILIGRRSUESTAYAdprewieostAFMGSSERCMLDYE|RRwenumoue
`
`
`BHI“SHYCRAY9SGREEIeORIEE“EREIOAN“2D
`
`
`
`wenuiapngosyDASEESOPMRSUD‘OMSBAMOREUHe
`
`42
`_]
`
`#
`
`@
`
`JJ
`
`@ ~ .,~
`
`,~ ~ .~ ~
`
`o
`o
`
`°CPlBaseoy
`
`~J
`
`
`
`122RSRSCRNAEURS£2ESHe41SOREBMETNAAL
`
`
`
`OAS44654AMCkYOSsAMEEAONOm
`
`
`
`°SEGRVOSSLACTHEMEORPOSBEHIIEF9271ae7BES
`
`~
`
`~
`o ~
`
`~,~ ~
`
`°ii°
`
`N
`
`
`
`
`
` COMMOBMNVO>OG"OWSGCOSBOLE‘212K
`
`HWe%28
`
`a
`
`es%Bgg
`
`atthe NLM and may be
`at th~ NLM a~d may be
`
`aww
`
`Page 2 of 15
`
`Page 2 of 15
`
`

`

`~ ~4< .~ ~
`
`0 o
`
`.~ zt ~’~, ~.
`
`o@
`
`o
`
`÷
`
`[]
`
`I~I ~
`
`d~ ~’~4J
`
`T
`
`m~ N*
`
`~J
`
`o
`
`.~
`
`o
`
`.3
`
`~~.
`~ .~ ~ ~, ~.
`
`@
`14-
`
`o
`
`This materia I was c~pied ~ ~ u~
`
`s’~ the NLM and m~y be
`
`Page 3 of 15
`
`

`

`~ ~ ~ u ~ ~ I~ ~ ~ ~ o~
`
`£2.64(BYU6BOX‘TSYUL241SoeeeCLMCr
`
`DERBHFLEORLeCOYBESBMY“DT
`
`DUTBUSSSYCoMYDBBEGeLORSE“>BGBelCCID]BSESEL
`
`TASEROMCRBIYILEAWASUBSRS
`
`NALDRESMMCREL2461MA!eeGeCNORS
`
`CESRROHBATISOSHWes<nRIOR‘aHBORee“7D
`
`“HETs@BEY2SBdelaeChCOSDORSRMSSPMOhs
`HIGEANGELNBBoALALAVASCHINSTSBSVdO%
`
`CEDRATIESMENTSBSCtTSReC2RE)SLRes
`
`‘WS!THEWOR—2TYSEWEADICREOUR
`
`
`
`
`
`USERRA(o9yeOA|ZOUIOINUMIPOSIPFIZhyNUSYSERACHARB
`
`HECORO©€PROD@ayes4yBoulo1wMiposiq°=f
`
`Ne2ENEOVOERRROXKA6—-CALYAMGERSSSEBMODY
`
`Co—fe]GSF71YE2BYSeMOBIT2SPOESCOEPREYFIOGCaeREYES*>GASHTNS+4021ERSODA
`OFLANABHAM‘9%CMFMOYRDNBMEO27RISRI
`
`CVSGREYSESESA]SYONCERRIE
`
`
`
`aN~
`
`(ACPAFE)BRLAMEAMAYRUBSS,.
`
`SVMOVELHUYOYlitemMIBYGPH21dy6SEYCLL9g
`
`a3
`
`Ub
`
`~ 42
`
`~e
`
`
`
`
`
`ANIA£404SOLUSAR2OGMEREM‘gE?TOD
`
`HAM-d‘DSTVO}6AEEUKMY2Ly9c0OR
`
`‘LVBBWMOEL6EROUCHSHse92SSRM2IV
`
`NCELABS
`
`"NCEWAI£IV820F@D
`
`~, ~’~’¢,~ ~ o
`
`eee.re2.+sBE°oteHSS°wSTEGL
`
`(PER2STE)SRANMAYEMoY.
`
`SAARASSe$BPISSEE
`
`aoa Me
`id
`
`a
`
`
`
`
`
`OG66T‘E1S~60S(8)2¢“ATHBA
`
`
`
`“NEEBWORSese
`
`e
`
`
`
`
`
`“NCESRIYASSYPSSBU
`
`bg
`
`re
`
`P
`
`inlYMNGADSROBELCEG2DSLH2ARNBLS~SI
`SUMEREALLOASLMABELES‘KyBOPiss2OLBE(FFBed):ed)Mee
`LARS“VleetFPRMOeeeaMe+oeLe4RUEYEEOS
`ALTER2YSDEOeBRLOUERFLEES
`
`
`BOB*CBSUMAEOPTUSLEOCSCMmMORs01LHS62
`
`IERoyYRStOGMGTAME(ASEBEALAL)30MSLEONCEOE
`
`
`CUEbRETOyEMG€L6GPUBLSIOBOEOFONCLUEvLid2UE(Py)Jouqiyuresepsue¢@2%,OHMEMoe‘ryeoxDeSALESIYROGM*9MORE?
`
`
`
`
`LALOLBOXOLERBGSOBREMAES“AGREEBie
`PIA‘CORMORORBRINOO“LALLEALREED
`
`227)BEGBEETRIEfFODFIR“USERRYMOALAE
`
`-) o ~ o
`
`I’, 42 h
`
`J ~’~ ~r~ ~
`
`o~~
`
`MGZeo“LDLSVe“RMSad©%£0046“BOERyc
`
`
`ABSTOURRMRKBRLUGHOOH
`
`
`
`eBBOR-..-BHO-.eSi-B4Ey-,2at
`
`FR+SWS=Be-5HBeten-Samy
`
`DMBCHEYHC200+MMSAGOPSLA
`
`
`
`
`
`O66I‘ZOS~00S‘(e)zo‘AYATRa
`
`
`
`
`
`(PexseTIF)BRASSSYRRAS,
`
`ba HOS
`
`8a Me
`
`(API=BETEE)BWRIWANES+<LAH
`
`
`
`(e-BATDE)BRACNASYeS
`
`
`
`
`
`0661‘8OG~E0S‘(S)7G‘AUATHAa
`
`&pIaSiang
`
`BET+CHINch-—S2eipt
`
`m_ ~ 1 B~N
`
`~NN
`
`[]
`F-
`
`.
`
`EMMEHAEY1S2SROPpeeay
`
`
`
`
`
`O66T“66F~C6F‘(€)2S“EV2VEHBa
`
`R ~ ¯
`
`~,~.
`
`.~ .
`
`mN~
`
`a ae ME
`
`g
`
`3i
`
`wom Me os
`
`This material was copied it ie
`
`a
`
`Page 4 of 15
`
`Page 4 of 15
`
`

`

`"6 k~ ~J
`~=o~
`
`fix
`
`,X ~
`
`6
`
`o
`
`N.5~d
`
`~’~. -I-u~,,~ ,,,.~
`.. ,~
`~ ,\
`~ @ (cid:128), ~
`
`~N o ~ u
`
`uN Z~
`N~NN
`
`xl
`
`b ~
`
`f~P~
`
`~o~1~-u
`
`~,~ ÷., x
`
`¯ . ~ i~ ~ ~ ~]
`
`~_~ ~
`
`~-~
`
`-u
`
`Thismaterial ...... pied~°1~ ~ ~
`
`at "~h~ N LM a~d may be
`~,ubject US Copyriy, ht Laws
`
`Page 5 of 15
`
`

`

`o~
`
`" "’ @ ~ "~ -
`
`t J
`
`]i-3
`
`:z-
`
`fi’,S
`
`"~- ~
`
`,
`
`~i~ ~ ~$ " ~-~ ~’’
`
`" ~.~
`
`.,,.
`
`~._o ~ ~ .~-,,
`
`~o ~.,d ~ ~-~ i"i ~,-~
`
`~
`
`o
`
`,~ ~_
`
`@ o~
`
`~ ~ "
`
`,.m
`
`~ ~ ÷ ,di ~ ~ ~.~ ~ u
`m~-.
`
`Th i~ m~te rial ~a~ ~opi~ I~ ~]I
`
`t’~ thin NLM and rncy b~
`
`Page 6 of 15
`
`

`

`545
`
`Butenafine hydrochroride (KP-363 : N-4-tert-butylbenzyl-N-l-methyl-l-naphtha-
`
`lene-methylamine hydrochloride) ©J~"-~9~’~’_~a~3 J: Ls’}],?~’~’~,~ ’*C-KP-363 .~,~
`
`}q,~ U 72 o 1% 14C-KP-363 0.2 ml (2 mg) ~ -~ A, ~ ,y b © :~[IJZh~ ~- 6 lt~t~J~.fJl~{,]" U ~,: ~.
`
`J~(_k©~lJ©~-h~,,~g) 6~’c, ~lJ~ barrier ~-~’]~7_1!?~ L~ ~- k #d:~]~JJ b
`
`KP-363, tolnaftate, c]otrimazole $3 3: L~ bifonazole © "1". mentagrophytes t~.%~’~" ,~ ~J-J
`
`t1~-~’~’~4.0, 15.6, 62.5 ~ok ~62.5 ug/g (-~) ~C~ 9, ÷)’7"t~--~tJ~"C’~llJ~L,
`
`L:~ (0.0125, 0.05, 0.39 ~ok b~ 0.39 #g/ml) t~.J~k.,-~-q~L-~7:o L~L, 1% KP
`
`a) ,J$~ in vitro ~NJ~N’J-~ ~. k, b) ~l]~]~b~t2
`
`ride (KP-363 : N-4-tert-butylbenzyl-N-methy]-1
`
`-naphthalenemethylamine hydrochloride) t~:]}21i¢/~
`
`t~ 48 It~-[~l]l~i~ I ~’~ 7". mentagrophytes ¢)t~
`
`~~t~-I~.,~l-j-$ ~. kh~6:~P,.’~, KP-363© in
`
`KP-363 (Lot 2000), clotrimazole (Lot 840614)
`J: ~ bifonazole (Lot 870306) ~ ~P~’~ L L:o
`Tolnaftate (Lot 8509) ~l~[J~j~{~.~22E-~ 3:911~.7,. U ¢L’o
`
`-363 ®~.@~&o)fJ~]~©’~t~J,,~Z’, 1% KP-363 0.2
`ml ~[i 24, 48 ~J ok L~ 72 ~[gJ~&~)]~l~rt~]Yg~$. "~ ~’L-~"
`
`2~31.5, 18.2.~okL~8.Spg/g-~59, NN72~[N~
`~’~o 7: mentagrophytes ¢)~NNN (0.012 #g/ml) o)
`
`6 ~Z DMSO -C, 2 ~:~t~:~ UTah, 0.1% Tween 80
`
`JJIIN~zkT~NU, 11000~0.03 #g/ml g)~}}~N~ k,
`
`72o ’~C-KP-363 (Lot 881111, J~]~}~}~]1{~44.3/~
`
`This m~teriml wa~ ~opied
`~tthe NLM ~nd m~y b~
`
`Page 7 of 15
`
`

`

`(i~ ~ ~ ¯ 52~ 3 ~)
`
`1o~
`
`tO’
`
`10’
`
`I0~
`
`a..,
`
`ea
`
`-- 50/t g/g
`
`(K1’-363 ~lJ~)
`
`o.sag/g
`
`I0~
`
`o
`
`1 ’.,’00
`
`IE1
`
`KP-363 I~3~’ff~) ~ tv ~ .v 1-/.~l~i~l~ (,)’~
`"C-KP-363 1%i/~ 0.2 ml (20pCi/2 mg) @ ~ ;~"
`
`9 ~ y - -cillU,~ o
`
`This material was copied
`atthe NLM arl~ mgY b.e
`
`Page 8 of 15
`
`

`

`547
`
`B)o
`
`~" A~ ~(cid:128)’ .~.
`
`,~1~$ ~ ~I~i~:~I¢)~IE~:- "~ ~ X" ~$, Freedman 5~
`~1 ~ I-~: griseofulvin ~: g)~z,l~-J-$~K~,
`griseofulvin ~ 16.5 l~g/ml 09 ~[~]~’L~;~/J~ b ?: ~ ~,
`
`KP-363, tolnaftate, clotrimazole ~ 3: ~ bifona-
`zole ©J’~ 7". mentagrophytes ~’i~: ~Z ~ ~, ~ ~ ~.t b ~ ~k
`
`1 ~btCo ~ 1 ~C~T3:5 ~:-, *}7"~-~g-~~"
`a)~’~’~’J: t~ KP-363 ~ ~ ~i <, 0.0125 pg/ml "T’~
`
`~(cid:128)~:. ~:~ 6 ~, ¢ ~ ~ +)---)P’~ 15%, PCP-Na ~"
`
`500 g~g/g, ~< :z~d b --- =~--A ~’ ~ 9 -1’ V 3,600 pg/g "~
`
`A~z,T,-Y 3:5 V., KP-363 ~;t 4)- 7" t~--~gt$-Ca9 MIC Cz
`
`i0 ~2 ~25 pg/ml ~ 9, ~r~l~bfz~ij~-~{#
`
`narrate, clotrimazole ~3: U~ bifonazole "O~4"ZL
`
`L, ~ft2~JJ~]~~ $~=~, in vitro ~Oi~P
`
`-~$~ <, 3:9 in vivo ~z~±©~4~"¢~~4~$11
`
`~42{~, 50{~, 144{~{~TL~~’5 :- ~ ~n,[J6~)~:
`
`KP-363, tolnaftate, clotrimazole .t-;J: U: bifo-
`nazole a)~ Trichophyton mentagrophytes f~z
`
`MIC (pg/g ~)
`
`MIC(;,g/ml)
`
`A*
`
`4.0
`15.6
`62.5
`62.5
`
`B**
`
`4.0
`15.6
`62.5
`62.5
`
`C***
`
`0.0125
`0.05
`0.39
`0.39
`
`KP-363
`Tolnaftate
`C1 otrimazole
`Bifonazole
`
`~7"~ (1~11)o KP-363 ~ tolnaftate, clotrimazole
`3: ZY bifonazole k [~]}~, fi~’i g ~T $ ~- k ~a J~ "9
`
`g/g ~ T. menlagrophytes tO~=~ff ~L~-Y $ ~- ~ ]~ 6-~-~
`
`,~. -~, KP-363 if) l%~t2,’~d~4’f:it~[t. ~ f~j~qn nf-~/l~f~]~)J~
`
`9, ~)~f,~z KP-363 a b~ 10/~g/gLXJ2©5~’:6’i~
`
`This material was copied
`at the NLM and may be
`
`Page 9 of 15
`
`

`

`548
`
`(~ ¯ 52~ 3 ~)
`
`"-E--"
`
`t,~D~’°>, 200~400 i,m ig’~O~l]~ll:O~t,~ z_ ~ li~J
`
`~. ~ ~ ~ ’~-"~o ~ ’I 09 24 ~ lh~ ~ 59 I, 000~I, 500 l,i’m 69
`
`435-439, 1988.
`
`2) Maeda 3" et al : Synthesis and antlfungal activity of
`butenafine hydrochloride (KP-363), a new ben.
`
`zylamine antifungal agent. Chem Pharma Bull ~{~
`
`~t~.
`
`3) Arika T et al : Effects of butenafine (KP-363), a new
`benzylamine derivative, on experimental dermato-
`
`phytosis in guinea pigs. Antimicrob Agents Chemother
`
`4) Arika T et al : Effects of butenafine (KP-363), a new
`benzylamine derivative, on experimental tinea pedis of
`guinea pigs. Antimicrob Agents Chemother ~’,’~
`5) i~ ..~:~flJ~r-<llfil~.~’J’ia)~IJ~e-l~J-j-~ Z, 3®;~
`t,~e
`IS~,~, 82 : 421-437, 1972,
`
`6) Freedman MH, Baxter RM and Walker GC: In
`vitro adsorption of griseofulvin by keratin substrates.
`
`J Invest Dermatol 38 : 199-208, 1962.
`
`~it,~, EII~ 85 : 517-524, 1975.
`
`12-]~d~$~ 85 : 413-415, 1975.
`9) Takahashi H et al: Clinical studies of fungicidal
`
`agents with respect to their relationships fn vitro and
`
`fn vfvo ; In vitro and in vivo evaluation of antifungal
`
`agents, (Iwata. K. and H. Vanden Bossche. ed), El-
`
`sevier Publishers, Amsterdam, 1986, 227-240.
`10) Bronaugh RL and Maibach HI: Percutaneous
`absorption--mechanism--method logy--drug deliv-
`ery. Marcel Decker, New York, 1985, 1-579.
`
`~ff~D~J~ : ~ 607 ~f~l.[ll’l.~lLqi’~’l@7~q,r~(Illl 14
`
`Page 10 of 15
`
`

`

`Activity of Topical Antifungals on Infected Sites
`
`--Skin Permeability and Adsorption to Horny Materials--
`
`Tadashi ARIKA, Toyoji HASE and Mamoru YOKOO
`
`Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
`Kyoto 607, Japan (Director : Dr. M. Nakanishi)
`
`549
`
`The permeability and retentivity of butenafine hydrochloride (KP-363, N-4-tert-butylbenzyl-N-methyl
`
`-1-naphthalenemethylamine hydrochloride) on the skin layer of guinea pigs were examined following
`
`percutaneous application. Two-tenths ml of a 1% ’4C-KP-363 solution was applied for 6 hours on a hair
`
`removed area of the dorsal skin of guinea pigs. At 6 hours after application, a high radioactivity correspond.
`
`ing to 50/,g/g or more of KP-363 was observed in the epidermis including the horny layer in which
`
`dermatophytes were lodged. Even at 24 hours, 10 t~g/ml or more of KP-363 still remained in ttle horny layer,
`
`indicating its high affinity to and long retention in this layer. Furthermore, the adsorption of various
`
`antifungal agents to the horny materials was also examined using powdered human hair. KP-363, tolnaftate,
`
`clotrimazole and bifonazole showed a stro!~g adsorption to the hair. Anti-Tn’chophyton menlagrophyles
`
`activity of the agents decreased’ when adsorbed into the hair ; i.e. the actdvity of KP-363 (MIC 0.0125 l~g/
`
`ml in Sabouraud dextrose broth) dropped to 4.0/tg/g hair, tolnaftate (0.05/tg/ml) to 15.6 l~g/g, clotrimazole
`
`(0.39 f*g/ml) to 62.5/~g/g and bifonazole (0.39 [~g/ml) to 62.5 ~g/g. It was, however, clarified that the
`
`concentration of KP-363 in the horny layer after topical application of 1% solution was high enough to inhibit
`
`the growth of T. mentagrophytes.
`
`This rneteri~l ~vas copied
`
`~tth~ NLM ~nd may b~
`
`Subject US Copyright Lew~
`
`Page 11 of 15
`
`

`

`(~g~ ’ 52~3 ~-. 1990)
`
`649
`
`~:~))J~2~10~] 121El (~), 13H] (i)
`
`"T 910 ~i~(cid:128)fflEl~ 1-13-6
`
`¯ ~ 0776-20-5060
`~{~i~ :
`
`1. ~ ~lj =jl~ )]l~
`
`/~,~ 0776-61-3111 (P~) 2325
`FAX 0776-61-3299
`
`34 [] El :~:~-~
`
`~ : gjm ~l!~ (~,~. E!i~>~ ~’-)
`
`~:~2~9)~28E~ (~), 29H (±)
`
`259-01 ~$~.)llh~¢EI~i~l~k~"$ 546
`7~ ~,;~ 0463-61-7111
`
`2. Etiology and treatment of keratin amyloidoses
`
`-~ :
`
`Ken Hashimoto (~Y ~ 4 :-")’[J~t~)
`3. New strategies for skin replacement and der-
`mal augmentation
`
`Medical mycology today
`
`Prof. D. W. R. Mackenzie
`
`Joseph McGuire (m--;~,::k:)
`
`(Director, Central Public Health Laboratory,
`
`1. }~I~.~.t~ DNA ~1~ a Progression
`
`2. ~,,~g~®~ ~ @,;g~
`
`London, UK; President, International Soci-
`
`ety for Human and Animal Mycology
`
`(ISHAM))
`
`2. -~ ~,~ ~ O/~
`
`3. ~,~ ~ ~ ¢ ~ ~++r"+~;~
`
`--Chemotaxonomy of fungi--
`
`4, Pemphigoid: bullous, gestational and cicatri-
`
`cal
`
`Grant J. Anhalt (~ s >’~-,T,7"$ >’~,~)
`
`5.
`
`Influence of different skin cleansing prepara-
`
`tions on the composition of the skin surface
`
`Hans Christian Korting ( .~ :~ :z~.>’~)
`
`~ ~ (°~-~,~,~)
`~t ~I~ll (~<l~]~)
`
`4. ;k~
`
`5. -(cid:128)~i~
`
`--Molecular approaches to funga] mor-
`phogenesis--
`
`--Recent progress in serodiagnosis and
`chemotherapy of fungal diseases--
`
`~2g~t~ (I~:~ ’ ~$’~)
`
`3. --~;~
`
`4. i~
`
`9o
`
`-~ 2 ~ 7 ~J #,~2~
`
`910-11 ~4:5~.~]W.~!til-F~ 23
`
`192-03 ]\~-~i~ 359
`
`rhi~ rn~t~ri~l ’~vas copied
`at th~ NLM and may be
`
`Page 12 of 15
`
`

`

`650
`
`~_~ : ~
`~ 0426-76-8211 (~}~ 258)
`0426-76-3003 (~)
`FAX 0426-74-9190
`
`~2~6~3~ (H)~
`
`~-~~
`~ 052-851-5511 (~ 2231)
`
`International Symposium on
`"Mast Cell-Differenciation and Regulatory
`Role in Immune and Allergic Response"
`and
`7th Annual Meeting of
`Skin Pharmacology Society
`
`~] : Symposium on Mast Cell
`
`1990 ~z 10 ~J 29 El
`7th Annual Meeting of SPS
`
`1990~10~30~, 31 [5
`
`~ : ~_l~-~g~
`"Y 730 )~hS~t’~P~:~ 1-5 (~z$fl~[~V~)
`~1~ 082-242-7777
`r=~ =~ : ¯ 734 ~$:~ff,~ 1-2-3
`
`~ 082-251-1111 (IAJ,~ 2334)
`
`8th Postgraduate Course in Medical
`Mycology (Dermatomycology)
`
`: 1990 ~F-10 YJ 12 E]~14 El
`: University of California San Francisco,
`
`pd]~’~- " University of California
`
`Extended Programs in Medical Education
`
`Room C-124, San Francisco, CA 94143-0742
`
`USA.
`
`European Society of Pediatric Dermatology
`
`~:1990t59~2115~23El
`
`rd]~-~ : Service de Dermatologie Pediatrique Hopital
`
`des Enfants, 168 cours de l’Argonne
`
`F-33077 Bordeaux Cedex, France
`
`This material was copied
`at the N LM and may be
`
`Page 13 of 15
`
`

`

`,T
`
`[i~ [] 2~ ~ ~ $,:[.J~ 52 ~ 2 -~ © p. 351~p. 359 ~. ~
`
`b ~. b ?z:~’J’[li~ NI-009~ [~ ~Y ~-~-’=b Z b
`
`p, 356 ~-F~ 6 3 {~ [] (31,9%) ~ (21,3%) ~-,~7to
`
`651
`
`This m~ta ria I wa~ copied
`at the N LM and may be
`
`Page 14 of 15
`
`

`

`652
`
`Gagoylism ~ ~jz~j~ ~ ~%-C ~ ~ 70 ~_ k "~’ib ;5 o Gagoylism,
`
`piebaldism (~(cid:128)~1~’~), Leopard ~-~- (~
`
`(~ ~- ~2)
`
`To
`
`~ I :~ 8000 P:]
`
`~ ~ ;~,~ }g52~’t~ 3 ~-
`(~)
`
`~z/~2 ~ 6 ~ 1 E{ ~.{~
`
`~ Brian T. Quinn
`
`~ ~iIt~i~t%~3T~l-1 ~:’~’812
`
`~ (092)-6sI-6210 (~@) ~ ~R~-22067
`(092)-641-1151 (f~)’(Fq~) 2503
`
`Th is m~terial was copied
`i~t the NLM ~n~ may ~e
`
`::f "~ ’~, P ~ ~ :~’- ::f 4 ,) X 2,
`
`Page 15 of 15
`
`